Compounds > pr-104a
Page last updated: 2024-12-11

pr-104a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PR-104A: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; PR-104A is the corresponding alcohol of PR104 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9848786
CHEMBL ID4438907
SCHEMBL ID366334
MeSH IDM0515481

Synonyms (23)

Synonym
680199-06-8
pr-104a
SCHEMBL366334
AZICEEZSDKZDHX-UHFFFAOYSA-N
2-((2-bromoethyl)-2-{[(2-hydroxyethyl)amino]carbonyl}-4,6-dinitroanilino)ethyl methanesulfonate
AKOS025147034
397986RF9L ,
3,5-dinitrobenzamide nitrogen mustard
2-(n-(2-bromoethyl)-2-(((2-hydroxyethyl)amino)carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate
benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-n-(2-hydroxyethyl)-3,5-dinitro-
2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-n-(2-hydroxyethyl)-3,5-dinitrobenzamide
2-((2-bromoethyl)(2-((2-hydroxyethyl)carbamoyl)-4,6-dinitrophenyl)amino)ethyl methanesulfonate
J-505203
2-[n-(2-bromoethyl)-2-(2-hydroxyethylcarbamoyl)-4,6-dinitroanilino]ethyl methanesulfonate
pr 104a
unii-397986rf9l
sn 27858
MS-29270
CHEMBL4438907
HY-14572
CS-0003452
2-((2-bromoethyl)(2-((2-hydroxyethyl)carbamoyl)-4,6-dinitrophenyl)amino)ethylmethanesulfonate
AKOS040749231

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Here, we report a population pharmacokinetic (PK) model for PR-104 and PR-104A in non-human species and in humans."( A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.
Choy, SS; Hicks, KO; Holford, NH; Melink, TJ; Patel, K; Wilson, WR, 2011)		0.84

Compound-Compound Interactions

ExcerptReferenceRelevance
"The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours."( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012)		0.38
"PR-104 was administered as a one-hour intravenous infusion combined with docetaxel 60 to 75 mg/m2 on day one given with or without granulocyte colony stimulating factor (G-CSF) on day two or administrated with gemcitabine 800 mg/m2 on days one and eight, of a 21-day treatment cycle."( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012)		0.38
" The MTD of PR-104 was 140 mg/m2 when combined with gemcitabine, 200 mg/m2 when combined with docetaxel 60 mg/m2, 770 mg/m2 when combined with docetaxel 60 mg/m2 plus G-CSF and ≥770 mg/m2 when combined with docetaxel 75 mg/m2 plus G-CSF."( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012)		0.38
" A recommended dose was identified for phase II trials of PR-104 of 770 mg/m2 combined with docetaxel 60 to 75 mg/m2 both given on day one of a 21-day treatment cycle supported by prophylactic G-CSF (NCT00459836)."( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012)		0.38
" PR-104 monotherapy elicited significant reductions in growth of Hep3B and HepG2 xenografts, and the combination with sorafenib was significantly active in all 4 xenograft models."( Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista, MR; Gu, Y; Guise, CP; Jamieson, SM; Nickel, JE; Patterson, AV; Pullen, SM; Wilson, WR, 2015)		0.42

Dosage Studied

ExcerptRelevanceReference
") dosing of humans, Beagle dogs, Sprague-Dawley rats and CD-1 nude mice."( A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.
Choy, SS; Hicks, KO; Holford, NH; Melink, TJ; Patel, K; Wilson, WR, 2011)		0.61
" At 270 mg/kg and lower dose levels, PR-104 did not induce solid tumor regressions, suggesting a steep dose-response relationship."( Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
Carol, H; Gorlick, R; Gu, Y; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Phelps, D; Reynolds, CP; Smith, MA; Wilson, WR; Wozniak, AW, 2011)		0.37
" PR-104 given weekly may be a suitable protocol for further clinical evaluation as a short course of treatment with fractionated radiotherapy or haematopoietic stem cell support, as its duration of dosing is restricted by delayed-onset and protracted thrombocytopenia."( A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.
Amies, K; Gu, Y; Hill, A; Jameson, MB; McKeage, MJ; Melink, TJ; Wilson, WR, 2011)		0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
2,4,6-trinitrotoluene catabolic processOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
2,4,6-trinitrotoluene catabolic processOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
NAD(P)H dehydrogenase (quinone) activityOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
6,7-dihydropteridine reductase activityOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
FMN bindingOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
oxidoreductase activityOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
identical protein bindingOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
protein homodimerization activityOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
oxidoreductase activity, acting on other nitrogenous compounds as donors, with NAD or NADP as acceptorOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytosolOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
membraneOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
cytosolOxygen-insensitive NAD(P)H nitroreductaseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1683168Selectivity index, ratio of IC50 for human DU145 cells under normoxic condition to IC50 human PC-3 cells under hypoxia condition incubated for 2 hrs followed by washed with fresh media incubated for 3 days by alamar blue assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer.
AID1683173Lipophilicity, logD of compound at pH 7.4 by microscale shake flask method2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer.
AID1683169Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 2 hrs under hypoxic condition followed washed with fresh media incubated for 3 days by alamar blue assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer.
AID1683170Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 2 hrs under normoxic condition followed by washed with fresh media incubated for 3 days by alamar blue assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer.
AID1581891Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis relative to CB1954/NfsB2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1683172Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs under hypoxic condition followed by washed with fresh media incubated for 3 days by alamar blue assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer.
AID1581890Substrate activity at Escherichia coli nitroreductase nfsA assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis relative to CB1954/NfsB2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1683167Selectivity index, ratio of IC50 for human PC-3 cells under normoxic condition to IC50 human PC-3 cells under hypoxia condition incubated for 2 hrs followed by washed with fresh media incubated for 3 days by alamar blue assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer.
AID1595314Substrate activity at Escherichia coli nitroreductase nfsB assessed as Kcat using NADH as cofactor at 0 to 800 mM in Tris-Cl buffer at pH 7.5 by spectrophotometric method2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID1683166Cytotoxicity against human PC-3 cells assessed as reduction in cell viability preincubated for 4 hrs in hypoxia and further incubated for 5 days in fresh medium by SRB assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer.
AID1683171Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs under normoxic condition followed by washed with fresh media incubated for 3 days by alamar blue assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer.
AID1595320Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km up to 80 mM using NADH as cofactor relative to CB1954/NfsB2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID1581877Substrate activity at Escherichia coli nitroreductase nfsB assessed as Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1581869Substrate activity at Escherichia coli nitroreductase nfsA assessed as Kcat using NADPH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1581883Substrate activity at Escherichia coli nitroreductase nfsA assessed as ratio of Kcat/Km using NADPH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometry based Michaelis-Menten plot analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1581876Substrate activity at Escherichia coli nitroreductase nfsA assessed as Km using NADPH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometry based Michaelis-Menten plot analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1595316Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
AID1581870Substrate activity at Escherichia coli nitroreductase nfsB assessed as Kcat using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1581884Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
AID1595315Substrate activity at Escherichia coli nitroreductase nfsB assessed as Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method2019European journal of medicinal chemistry, Jun-01, Volume: 171PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (16.00)29.6817
2010's18 (72.00)24.3611
2020's3 (12.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.59 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (8.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (92.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		2.1110pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.110isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		2.4520aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
etanidazole
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.. etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.		2.1510C-nitro compound;
imidazoles;
monocarboxylic acid amide		alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		2.1510C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
sulforaphane
sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.		7.1310isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.0510acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
deoxycytidine
[no description available]		4.3711pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		4.3711organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.15101,2,3-triazole
tretazicar
tretazicar: minor descriptor (75-84); on-line & Index Medicus search AZIRIDINES (75-84)		2.8530
sn 23862
5-(N,N-bis(2-chloroethyl)amino)-2,4-dinitrobenzamide: RN & structure given in first source		2.6320
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		4.3711secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
sorafenib
[no description available]		2.1110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
2-(2-nitro-1h-imidazol-1-yl)-n-(2,2,3,3,3-pentafluoropropyl)acetamide
2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide: a pentafluorinated derivative of etanidazole		2.1510
pr-104
PR-104: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; structure in first source		6.1862
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		7.0310aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Prostate
[description not available]		02.6920
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.6920
Benign Neoplasms
[description not available]		06.0652
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		06.0652
Hepatocellular Carcinoma
[description not available]		02.1110
Cancer of Liver
[description not available]		02.1110
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.1110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.1110
Leukemia, Lymphoblastic, Acute, T Cell
[description not available]		02.1110
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.		02.1110
Cancer of Colon
[description not available]		02.1310
Colonic Neoplasms
Tumors or cancer of the COLON.		02.1310
Cancer of Cervix
[description not available]		02.0610
Cancer of Lung
[description not available]		02.0610
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.0610
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0610
Adverse Drug Event
[description not available]		04.3711
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		04.3711